Quick Dispatch:
Your tirzepatide surpass Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial orders ship within 1-2 business days.
Delivery Options:
Order Tracking:
You'll receive a tracking link by email once your tirzepatide surpass Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial ships.
Need Help?
Questions about tirzepatide surpass Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial, sizing, or delivery? We're just an email away.
Live Shipping Estimates:
Enter your location at checkout to see available shipping methods and costs for tirzepatide surpass Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial in your area.
SURPASS-CVOT Published: Large Trial Confirms CVD Efficacy of Tirzepatide
23.01
Tirzepatide for diabetes: on track to SURPASS current therapy
27.94
SURPASS-1 Trial of Tirzepatide in Type 2 Diabetes
23.59
Tirzepatide Matches Dulaglutide in Large CV Outcomes Trial: SURPASS-CVOT
28.23
00188-7/asset/2c20a909-3c0e-4be2-9bc4-c699b73fc56e/main.assets/gr2_lrg.jpg)
Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial
20.59
Diabetes Distilled: “Twincretin” tirzepatide significantly SURPASSes comparator effects on glucose, weight and quality of life
26.92
SURPASS-2: A Study of Tirzepatide Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes – My Endo Consult
20.65
